A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer.
We spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.
California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
A new study is suggesting that combining BET inhibitors with other agents targeting protein kinases might make them more effective in treating cancer.
Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease epithelial ovarian cancer.
NEW ORLEANS – A new type of antibody-drug conjugate (ADC) platform may pave the way to help patients with ovarian cancer and non-small cell lung cancer.
An experimental therapeutic vaccine for the treatment of ovarian cancer is now showing promise and on February 3, 2016, was granted Fast Track Designation by the US Food and Drug Administration.
Research scientists have developed a test that may be able to aid in the diagnosis of ovarian cancer at an early stage.
A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients